Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "st
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... 2008 MaxCyte, Inc., a,clinical-stage therapeutics company ... systems, announces that Anthony Recupero, Ph.D.,Vice President ... Tuesday,April 8, 2008, at 2:00PM at the ... Recupero,s presentation will discuss the development of,engineered ...
... Bluestar Silicones,introduces a new range of Silbione(R) brand ... market that provide a unique combination,of strong physical ... durometers., These new low durometer products incorporate ... to 70- ShA LSR product,line, including easy processing, ...
... Center for ... Critical Path Immunology -, SAN FRANCISCO, April 7, ... B. Kantor, Ph.D. has,joined the company in the position of Chief ... Officer. Prior to,joining ITI, Dr. Kantor served as Executive Director of ...
Cached Biology Technology:Bluestar Silicones Introduces Three New Soft and Durable Liquid Silicone Rubber Products 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 3Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 4
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... to display the earliest signs of Parkinson,s disease using the ... the disease. The mouse model, which expresses the same ... of constipation and other gastrointestinal problems that are a common ... result, researchers say, these animals could serve as a means ...
... Bethesda, MarylandThe American Association of Anatomist,s (AAA) presented its ... Meeting in Anaheim. This year,s honors went to: ... Dept. of Cell and Developmental Biology at SUNY Upstate ... the 2010 Henry Gray/ Lippincott Williams & Wilkins Scientific ...
... in Spanish . ANN ARBOR, Mich. ... treat breast cancer by targeting cancer stem cells -- the ... according to a new study from researchers at the University ... a component of broccoli and broccoli sprouts, in both mice ...
Cached Biology News:UCSF transgenic mouse mimics Parkinson's earliest symptoms 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 3Broccoli component limits breast cancer stem cells, U-M study finds 2
Donor Horse Serum US Origin...
Mouse Aminopeptidase P2/XPNPEP2 Biotinylated Aff Pur PAb Keywords: AminopeptidaseP2, Metalloproteinase, Metalloprotease, X-Prolyl Aminopeptidase 2, X-Pro Aminopeptidase 2, Membrane-bound Prote...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
... from egg white. The extinction coefficient , ... 10 mM phosphate-buffered saline, pH 7.4, ... azide and 50% glycerol. Avidin (from egg white) ... purified by molecular sieving and is ...
Biology Products: